Literature DB >> 3542943

Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria.

D A Leigh, F X Emmanuel, V J Petch.   

Abstract

Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa. All patients had severe underlying abnormalities and infection usually followed urethral catheterization. The infecting organisms were eradicated from the urine of all patients during therapy and 89% were still clear five to nine days after treatment. At one month follow up the cure rate had fallen to 64%. An increase in resistance to ciprofloxacin was seen in three of the ten failures in infections caused by Ps. aeruginosa. Therapy was well tolerated and few side effects were seen. Ciprofloxacin is a valuable addition to the range of antimicrobial agents available for the treatment of Ps. aeruginosa urinary tract infections particularly in domiciliary practice.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3542943     DOI: 10.1093/jac/18.supplement_d.117

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

2.  Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens.

Authors:  D Desgrandchamps; J Munzinger
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 3.  Clinical experience with ciprofloxacin in the treatment of urinary tract infections: a review.

Authors:  H van Poppel; V Chyský; R Hullmann; L Baert
Journal:  Infection       Date:  1988       Impact factor: 3.553

4.  Complicated urinary tract infection in adults.

Authors:  L E Nicolle
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-11       Impact factor: 2.471

5.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

6.  Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study.

Authors:  G D Fang; C Brennen; M Wagener; D Swanson; M Hilf; L Zadecky; J DeVine; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 7.  Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

Authors:  A Dalhoff
Journal:  Infection       Date:  1994       Impact factor: 3.553

Review 8.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 9.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.